A Phase 2 Study on the Safety and Efficacy of the Anti-BAFF-R Monoclonal Antibody, ESG206, in Patients With Systemic Lupus Erythematosus
Clinical trial NCT07760155 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07760155
- Sponsor
- Shanghai Escugen Biotechnology Co., Ltd
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-09-01
- Primary completion
- 2028-03-31
- Enrollment
- 40
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.